Merck & Co Inc
MRKHealthcare|Drug Manufacturers - General|USA
$120.85
+0.00 (+0.00%)
DCF (FCF)
$75.40
Tangible Book
$1.76
Graham Number
$18.83
Earnings Power
$41.17
Upcoming Data Readouts (37)
Oct 2026
Est. completion
Oct 2026
Est. completion
P2Essential Thrombocythemia
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
NCT04262141n=4
Oct 2026
Est. completion
P2Cervix Cancer
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
NCT06266338n=30
Nov 2026
Est. completion
P1Acute Myeloid Leukemia
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05597306n=18
Dec 2026
Est. completion
Dec 2026
Est. completion
P2Uveal Melanoma
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05524935n=37
Dec 2026
Est. completion
Dec 2026
Est. completion
P1Multiple Myeloma in Relapse
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050n=100
Jan 2027
Est. completion
P2Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
NCT04666740n=63
Jan 2027
Est. completion
P2Cervical Intraepithelial Neoplasia
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
NCT04712851n=25
Feb 2027
Est. completion
P2Renal Cell Carcinoma (RCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540n=118
Apr 2027
Est. completion
P2Anal Cancer
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT06493019n=23
Apr 2027
Est. completion
P1P2Melanoma
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
NCT04971499n=26
May 2027
Est. completion
P3Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588n=556
Jul 2027
Est. completion
P2SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
NCT05623319n=60
Jul 2027
Est. completion
P2Beta-Thalassemia
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724n=99
Sep 2027
Est. completion
P2Advanced Solid Tumor
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654n=200
Oct 2027
Est. completion
Nov 2027
Est. completion
P2Malignant Neoplasm
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596n=250
Nov 2027
Est. completion
P2Esophageal Cancer
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
NCT06123338n=49
Awaiting Results (35)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2026
P1
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
NCT05081180Sep 2026
P1P2
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536Aug 2026
P2
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
NCT04745988Jul 2026
P1
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
NCT04846920Jul 2026
P1
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03932409Jun 2026
P3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Apr 2026
P2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668